Ciencias de la Salud
Domaine de connaissance
Jesús María
Bañales Asurmendi
Publications dans lesquelles il/elle collabore avec Jesús María Bañales Asurmendi (111)
2024
-
Fibroblast-Derived Lysyl Oxidase Increases Oxidative Phosphorylation and Stemness in Cholangiocarcinoma
Gastroenterology, Vol. 166, Núm. 5, pp. 886-901.e7
-
Proceedings of the 5th Meeting of Translational Hepatology, organized by the Spanish Association for the Study of the Liver (AEEH)
Gastroenterologia y Hepatologia
-
Serum identification of at-risk MASH: The metabolomics-advanced steatohepatitis fibrosis score (MASEF)
Hepatology, Vol. 79, Núm. 1, pp. 135-148
-
Stratified analyses refine association between TLR7 rare variants and severe COVID-19
Human Genetics and Genomics Advances, Vol. 5, Núm. 4
-
The biochemical pattern defines MASLD phenotypes linked to distinct histology and prognosis
Journal of Gastroenterology, Vol. 59, Núm. 7, pp. 586-597
2023
-
A second update on mapping the human genetic architecture of COVID-19
Nature
-
A3907, a systemic ASBT inhibitor, improves cholestasis in mice by multiorgan activity and shows translational relevance to humans
Hepatology (Baltimore, Md.), Vol. 78, Núm. 3, pp. 709-726
-
Erratum to: Mapping the human genetic architecture of COVID-19 (Nature, (2021), 600, 7889, (472-477), 10.1038/s41586-021-03767-x)
Nature
-
Identification of taxonomic changes in the fecal bacteriome associated with colorectal polyps and cancer: potential biomarkers for early diagnosis
Frontiers in Microbiology, Vol. 14
-
Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis, and prognostication of cholangiocarcinoma
Journal of Hepatology, Vol. 79, Núm. 1, pp. 93-108
-
Mechanisms by which the cystic fibrosis transmembrane conductance regulator may influence SARS-CoV-2 infection and COVID-19 disease severity
FASEB Journal, Vol. 37, Núm. 11
-
Screening uptake of colonoscopy versus fecal immunochemical testing in first-degree relatives of patients with non-syndromic colorectal cancer: A multicenter, open-label, parallel-group, randomized trial (ParCoFit study)
PLoS Medicine, Vol. 20, Núm. 10
-
Targeting the Heterogeneous Tumour-Associated Macrophages in Hepatocellular Carcinoma
Cancers, Vol. 15, Núm. 20
-
miR-21-5p promotes NASH-related hepatocarcinogenesis
Liver International, Vol. 43, Núm. 10, pp. 2256-2274
2022
-
Association between Metabolic Disorders and Cholangiocarcinoma: Impact of a Postulated Risk Factor with Rising Incidence
Cancers, Vol. 14, Núm. 14
-
Bridging the equity gap in patient education: the biliary tract cancer BABEL project
The Lancet Oncology
-
Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry
Journal of Hepatology, Vol. 76, Núm. 5, pp. 1109-1121
-
Cholangiocarcinoma progression depends on the uptake and metabolization of extracellular lipids
Hepatology, Vol. 76, Núm. 6, pp. 1617-1633
-
Detailed stratified GWAS analysis for severe COVID-19 in four European populations
Human Molecular Genetics, Vol. 31, Núm. 23, pp. 3945-3966
-
Genetics, pathobiology and therapeutic opportunities of polycystic liver disease
Nature Reviews Gastroenterology and Hepatology, Vol. 19, Núm. 9, pp. 585-604